The post discusses Robin, a multi-agent system aimed at automating scientific discovery. Comments reflect skepticism about the efficacy of Robin and explore wider issues in research, including the role of AI in academic settings and the challenges of profit-driven pharmaceuticals. Some users express concern that AI could lead to a reduced role for human researchers, relegating them to experimental work under AI's guidance. There's a recognition of the potential for rediscovering uses for out-of-patent drugs, but concerns are raised about the general academic and corporate interest in such avenues due to profit motives. Furthermore, the discussion tackles the notion of focusing on derivative compounds rather than seeking out novel solutions, indicative of the narrow pathways that can emerge when academic and corporate interests collide with scientific inquiry.